# Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer

> **NCT01870791** · PHASE2 · TERMINATED · sponsor: **University Hospitals, Leicester** · enrollment: 21 (actual)

## Conditions studied

- Esophageal Neoplasm
- Gastric Neoplasm

## Interventions

- **DRUG:** Omegaven

## Key facts

- **NCT ID:** NCT01870791
- **Lead sponsor:** University Hospitals, Leicester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Interim analysis
- **Last updated:** 2016-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870791, "Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01870791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*